Login to Your Account



XOMA, Genentech Set Back On Development Of Xanelim

By Kim Coghill


Monday, April 8, 2002
XOMA Ltd.’s stock took a painful hit Friday when the company and its partner, Genentech Inc., released poor preliminary data from a pharmacokinetic study of Xanelim, a psoriasis drug. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription